Royal Philips has received FDA 510(k) clearance for its Spectral CT Verida system, a detector-based spectral CT platform that integrates artificial intelligence into image reconstruction.

The Amsterdam-based health technology company said the system combines dual-layer detector technology with a deep learning reconstruction engine designed to reduce image noise and improve image quality across a range of CT applications. The system’s “always-on” spectral imaging captures high- and low-energy data in a single scan, allowing clinicians to generate both conventional and spectral images without additional acquisitions or workflow changes.

Verida includes what Philips describes as a third-generation dual-layer detector with built-in noise reduction, alongside software enhancements aimed at improving processing speed and system performance. According to the company, the platform can reconstruct up to 145 images per second, with full exam results available in under 30 seconds.
“With FDA clearance for Verida, we are bringing the next evolution of spectral CT to more markets,” said Dan Xu, business leader of CT at Philips. “By combining always-on spectral imaging with AI-powered reconstruction, Verida enables clinicians to see more, first time right; supporting faster, more informed decisions and expanding the role of CT across clinical pathways.”

The system is intended for diagnostic imaging across radiology, interventional radiology, cardiology, and oncology, including use in treatment planning and radiation therapy simulation. It supports a range of applications, including head, cardiac, vascular, and whole-body imaging, and is cleared for low-dose lung cancer screening when used within established protocols.

By enabling simultaneous access to spectral and conventional data, the system is designed to support tissue characterization and material differentiation without requiring repeat scans, which may reduce exam time and streamline clinical workflows.

CT Homepage